Cancer News and Research

Latest Cancer News and Research

MaxCyte, Medinet agree to amend License, Development and Supply Agreement

MaxCyte, Inc., and Medinet Co. Ltd., announced today that they have agreed to amend their License, Development and Supply Agreement for expansion of Medinet's right to use MaxCyte's cell loading technology in Asia Pacific markets.

9 Apr 2010

Today's opinions and editorials

In its most frightening version to date, the new Big Lie about health care reform is that it will require the Internal Revenue Service to hire "16,500 armed bureaucrats" to enforce the coming requirement that those who can afford it must purchase insurance (Eric Zorn, 4/8).

9 Apr 2010

Research roundup: The effects of health IT, doctor-owned treatment centers, long-term care issues

Physician-Ownership Of Ambulatory Surgery Centers Linked To Higher Volume Of Surgeries - The authors analyzed data from Florida, using the Healthcare Cost and Utilization Project's State Ambulatory Surgery Databases, revealing "a significant association between physician-ownership of surgicenters and greater use" of certain outpatient procedures.

9 Apr 2010

NexMed expands San Diego facilities to accommodate pre-clinical research services

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that it has expanded its San Diego facilities to accommodate an increase in demand for its pre-clinical research services.

9 Apr 2010

DISH should be considered an important cause of dysphagia among older adults: Study

Diffuse idiopathic skeletal hyperostosis is a common but often unrecognized systemic disorder observed mainly in elderly people. All papers related to DISH demonstrate a consistent and marked increase of the disease with advancing age. Various local structural lesions such as oropharyngeal tumors, vascular pathologies, retropharyngeal abscesses, and anterior cervical osteophytes may lead to mechanical esophageal dysphagia.

9 Apr 2010

Gamma-tocotrienol kills prostate tumour cells in animal model studies

Researchers from Davos Life Science in Singapore, in collaboration with scientists at the University of Hong Kong, have shown that gamma-tocotrienol, a member of the vitamin E family, is potent in killing prostate tumour cells in animal model studies. This research was reported this week in the latest edition of Pharmacology.

9 Apr 2010

A*STAR announces fifth major collaboration with Italian research centres and universities

Two research units under Singapore's Agency for Science, Technology and Research (A*STAR), the Experimental Therapeutics Centre (ETC) and Singapore Immunology Network (SIgN), are collaborating with Italy's Siena Biotech S.p.A. to develop new drugs and targeted antibodies respectively, which will potentially help millions of cancer and bone loss patients across the world. This is the fifth major collaboration A*STAR has with research centres and universities in Italy .

9 Apr 2010

BIBA Research's TAVI report to be released

BIBA Research, the UK-based market research specialists for the medical technology industry, announced today that the latest findings from their Transcatheter Heart Valve report will be released on 26 April. The report covers the data period January-March 2010 and is part of BIBA Research's long-established European Cardiovascular Monitor.

9 Apr 2010

Gelatinase B expression enhanced in gastric cancer compared to normal gastric mucosa

Gastric cancer in Mexico is the most frequent gastrointestinal malignant neoplasm. Several precursor conditions, such as chronic gastritis, have been associated with the development of gastric cancer. The gelatinases MMP-2 and MMP-9, members of the metalloproteinase family, are fundamental enzymes in extracellular matrix remodelling. The extracellular matrix is composed of secreted molecules outside cells which provides structural support and regulates cell behaviour.

9 Apr 2010

Investment report on Radient Pharmaceuticals from StockPreacher.com

StockPreacher.com announces an investment report featuring Radient Pharmaceuticals Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

9 Apr 2010

Mayo Clinic researchers to present XOMA 052 data at 101st AACR Annual Meeting

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that researchers from the Mayo Clinic will be presenting data on the use of XOMA's high-affinity antibody to interleukin-1 beta (IL-1 beta), XOMA 052, in myeloma at the 101st Annual Meeting of the American Association of Cancer Research (AACR).

9 Apr 2010

Drugs that affect methylation state of genes could reverse autism's effects: The FASEB Journal

A new discovery raises hope that autism may be more easily diagnosed and that its effects may be more reversible than previously thought. In a new study appearing online in The FASEB Journal, scientists have identified a way to detect the disorder using blood and have discovered that drugs which affect the methylation state of genes could reverse autism's effects.

9 Apr 2010

Non-psychoactive cannabis to be unveiled at Annual National Clinical Conference on Cannabis Therapeutics

The availability of a new type of medical cannabis strain will be presented for the first time by Steve DeAngelo, who has been featured on CNN, The Wall Street Journal, Fortune Magazine, and The New York Times as Executive Director of one of the nation's top model and non-profit medical cannabis dispensaries, Harborside Health Center in Oakland, California.

9 Apr 2010

New methodology helps investigate unfolding of DNA

NYU Langone Medical Center researchers have developed a powerful new method to investigate the discrete steps necessary to turn on individual genes and examine how the process goes wrong in cancer and other diseases. The finding, based on seven years of research and described in the April 9 issue of Molecular Cell, allows scientists to investigate the unfolding of DNA, a process required for gene activation.

9 Apr 2010

Inovio Biomedical receives $2.8M grant to develop DNA vaccine for HCV

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that the company and its collaborators from Drexel University, Cheyney University, and the University of Pennsylvania have received a $2.8 million grant to develop a DNA vaccine to treat hepatitis C virus.

9 Apr 2010

Recql5 identified as a tumor suppressor in GI tract

Recql5 is a member of the mammalian RecQ helicase family. Genetic mutations that result in loss of RecQ helicase activity give rise to disorders that are associated with cancer predisposition and premature aging, such as Bloom, Werner, and Rothmund-Thomson syndromes. This class of enzymes is best known for their role in maintaining the integrity of the genome to prevent oncogenic mutations.

9 Apr 2010

Mayo Clinic Health Letter: UV light slows skin cell overgrowth, alters immune system

Ultraviolet light -- a culprit behind sunburns, wrinkles and skin cancer -- offers benefits for some skin conditions, according to the April issue of Mayo Clinic Health Letter.

9 Apr 2010

IFN therapy for chronic hepatitis C must be individualized and optimized for efficacy

The efficacy of interferon (IFN) therapy depends on the hepatitis C virus (HCV) genotype, pretreatment viral load and early viral kinetics. Thus, IFN therapy must be individualized and optimized according to the virological and clinical status of each patient.

9 Apr 2010

Biosense Webster obtains first Ethics Committee approval for CLARITY study

Biosense Webster announces that this week it has obtained its first Ethics Committee approval for the CLARITY study, comparing the 1-year efficacy, safety and efficiency of CARTO(R) 3 System-guided radiofrequency ablation using the NAVISTAR(R) THERMOCOOL(R) Catheter versus fluoroscopy-guided radiofrequency ablation using the Pulmonary Vein Ablation Catheter(R) (PVAC(R), Ablation Frontiers, Medtronic) in patients with paroxysmal atrial fibrillation.

9 Apr 2010

Researchers show iRGD peptide increases treatment efficacy against cancer

Researchers have shown that a peptide (a chain of amino acids) called iRGD helps co-administered drugs penetrate deeply into tumor tissue. The peptide has been shown to substantially increase treatment efficacy against human breast, prostate and pancreatic cancers in mice, achieving the same therapeutic effect as a normal dose with one-third as much of the drug.

9 Apr 2010

Cancer News and Research

Latest Cancer News and Research

MaxCyte, Medinet agree to amend License, Development and Supply Agreement

Today's opinions and editorials

Research roundup: The effects of health IT, doctor-owned treatment centers, long-term care issues

NexMed expands San Diego facilities to accommodate pre-clinical research services

DISH should be considered an important cause of dysphagia among older adults: Study

Gamma-tocotrienol kills prostate tumour cells in animal model studies

A*STAR announces fifth major collaboration with Italian research centres and universities

BIBA Research's TAVI report to be released

Gelatinase B expression enhanced in gastric cancer compared to normal gastric mucosa

Investment report on Radient Pharmaceuticals from StockPreacher.com

Mayo Clinic researchers to present XOMA 052 data at 101st AACR Annual Meeting

Drugs that affect methylation state of genes could reverse autism's effects: The FASEB Journal

Non-psychoactive cannabis to be unveiled at Annual National Clinical Conference on Cannabis Therapeutics

New methodology helps investigate unfolding of DNA

Inovio Biomedical receives $2.8M grant to develop DNA vaccine for HCV

Recql5 identified as a tumor suppressor in GI tract

Mayo Clinic Health Letter: UV light slows skin cell overgrowth, alters immune system

IFN therapy for chronic hepatitis C must be individualized and optimized for efficacy

Biosense Webster obtains first Ethics Committee approval for CLARITY study

Researchers show iRGD peptide increases treatment efficacy against cancer

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in